Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2008

View Archived Issues

Targeting galectin-1 may be useful to prevent pregnancy loss

Studies support serotonin inverse agonist combination therapy for schizophrenia

New site-directed nanoparticle delivery system useful to treat ocular inflammation in vivo

Cognition-enhancing activity of novel inverse agonist of GABA-A alpha 5 subunit receptors

Modulation of LR11 protein levels by dietary DHA may be beneficial for AD prevention

AstraZeneca submits sNDAs for Seroquel XR tablets

Can-Fite collaborates with academic institutes to develop CF-102

Efexor XL indication in U.K. now includes moderate-severe generalized SAD/social phobia

Innocoll doses first patient in phase III gentamicin surgical implant trial

NeoPharm files IND for novel docetaxel liposomal delivery system

Pfizer completes tender offer relating to outstanding shares of Coley Pharmaceutical

Recent Jerini patent discloses novel agents for ocular disorders

Pfizer launches Ecalta for invasive candidiasis in non-neutropenic patients

Positive results reported for Zybrestat in platinum-resistant ovarian cancer

Prana Biotechnology completes phase IIa trial of PBT-2 in Alzheimer's disease

Recent patents impart novel analgesic agents

FDA approves Sciele Pharma's new Sular formulation

FDA assigns priority review status to Schering-Plough's NDA for sugammadex

New HIV aspartyl protease inhibitors disclosed in recent Tibotec patent

Recent patents describe new antidiabetic agents

Sepracor and Bial collaborate on antiepileptic compound in U.S. and Canada

Positive preclinical ocular penetration data reported for topical Zybrestat in ophthalmology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...